| UPR, autophagy, and mitochondria crosstalk underlies the ER stress response D Senft, AR Ze’ev Trends in biochemical sciences 40 (3), 141-148, 2015 | 990 | 2015 |
| Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells R Besch, H Poeck, T Hohenauer, D Senft, G Häcker, C Berking, ... The Journal of clinical investigation 119 (8), 2399-2411, 2009 | 521 | 2009 |
| Ubiquitin ligases in oncogenic transformation and cancer therapy D Senft, J Qi, ZA Ronai Nature Reviews Cancer 18 (2), 69-88, 2018 | 385 | 2018 |
| Regulators of mitochondrial dynamics in cancer D Senft, AR Ze’ev Current opinion in cell biology 39, 43-52, 2016 | 279 | 2016 |
| Precision oncology: the road ahead D Senft, MDM Leiserson, E Ruppin, AR Ze’ev Trends in molecular medicine 23 (10), 874-898, 2017 | 167 | 2017 |
| Adaptive stress responses during tumor metastasis and dormancy D Senft, AR Ze'ev Trends in cancer 2 (8), 429-442, 2016 | 101 | 2016 |
| RACK1 function in cell motility and protein synthesis V Gandin, D Senft, I Topisirovic, ZA Ronai Genes & cancer 4 (9-10), 369-377, 2013 | 78 | 2013 |
| Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1 D Senft, C Berking, SA Graf, C Kammerbauer, T Ruzicka, R Besch PLoS One 7 (1), e30821, 2012 | 60 | 2012 |
| Ubiquitin ligases in cancer immunotherapy–balancing antitumor and autoimmunity Y Fujita, R Tinoco, Y Li, D Senft, AR Ze’ev Trends in molecular medicine 25 (5), 428-443, 2019 | 43 | 2019 |
| Immunogenic, cellular, and angiogenic drivers of tumor dormancy‐a melanoma view D Senft, ZA Ronai Pigment cell & melanoma research 29 (1), 27-42, 2016 | 43 | 2016 |
| The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival T Hohenauer, C Berking, A Schmidt, S Haferkamp, D Senft, ... EMBO molecular medicine 5 (6), 919-934, 2013 | 39 | 2013 |
| In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-X L and Mcl-1 but in the absence of active BH3-only proteins D Senft, A Weber, F Saathoff, C Berking, MV Heppt, C Kammerbauer, ... Cell death & disease 6 (11), e1996-e1996, 2015 | 26 | 2015 |
| Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice S Ebinger, C Zeller, M Carlet, D Senft, JW Bagnoli, WH Liu, ... haematologica 105 (12), 2855, 2020 | 17 | 2020 |
| A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia D Senft, I Jeremias Experimental hematology 69, 1-10, 2019 | 16 | 2019 |
| In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets M Carlet, K Völse, J Vergalli, M Becker, T Herold, A Arner, D Senft, ... Nature communications 12 (1), 5655, 2021 | 11 | 2021 |
| Tumor Cell Dormancy—Triggered by the Niche D Senft, I Jeremias Developmental cell 49 (3), 311-312, 2019 | 8 | 2019 |
| A reporter system for enriching CRISPR/Cas9 knockout cells in technically challenging settings like patient models WH Liu, K Völse, D Senft, I Jeremias Scientific Reports 11 (1), 12649, 2021 | 6 | 2021 |
| ATF2 alters melanocyte response and macrophage recruitment in UV-irradiated neonatal mouse skin D Senft, A Sorolla, A Dewing, G Claps, E Lau, GJ Walker, ZA Ronai Pigment cell & melanoma research 28 (4), 481, 2015 | 6 | 2015 |
| In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance AK Wirth, L Wange, S Vosberg, KO Henrich, C Rausch, E Özdemir, ... Leukemia 36 (12), 2863-2874, 2022 | 5 | 2022 |
| X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL M Carlet, K Schmelz, J Vergalli, T Herold, D Senft, V Jurinovic, ... EMBO Molecular Medicine 15 (1), e14557, 2023 | 3 | 2023 |
